Idenix v. Gilead: The enablement and written description limits of a genus claim (Journal of Generic Medicine)

Goodwin IP Litigation members Keith Zullow and Sean Anderson wrote about the context surrounding the Federal Circuit’s Idenix decision and the Supreme Court’s decision not to hear the case. Read the by line in the Journal of Generic Medicine here.